Gilead Sciences, Inc.
GILD
$120.14
$0.120.10%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.81% | 4.68% | 6.04% | 3.32% | 1.54% |
| Total Other Revenue | 0.00% | -- | -- | -- | -- |
| Total Revenue | 3.81% | 4.69% | 6.04% | 3.32% | 1.54% |
| Cost of Revenue | -1.21% | 1.12% | 3.85% | 8.22% | 11.32% |
| Gross Profit | 5.27% | 5.72% | 6.67% | 2.00% | -0.99% |
| SG&A Expenses | 4.00% | -4.00% | -1.01% | -12.03% | -12.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.36% | -1.32% | 1.45% | -2.96% | 0.14% |
| Operating Income | 8.05% | 16.21% | 14.86% | 15.75% | 4.05% |
| Income Before Tax | 367.90% | 534.88% | -89.93% | -97.55% | -79.06% |
| Income Tax Expenses | 75.89% | 39.38% | -83.09% | -95.53% | -73.49% |
| Earnings from Continuing Operations | 510.94% | 1,202.40% | -91.45% | -98.04% | -81.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -74.47% | -52.38% |
| Net Income | 499.34% | 1,132.44% | -91.53% | -97.86% | -80.80% |
| EBIT | 8.05% | 16.21% | 14.86% | 15.75% | 4.05% |
| EBITDA | 6.44% | 12.79% | 12.14% | 14.30% | 6.40% |
| EPS Basic | 501.26% | 1,144.01% | -91.54% | -97.87% | -80.78% |
| Normalized Basic EPS | 7.56% | 15.25% | 13.53% | 15.39% | 4.83% |
| EPS Diluted | 522.15% | 1,273.20% | -92.09% | -98.39% | -81.49% |
| Normalized Diluted EPS | 7.16% | 15.06% | 13.89% | 15.92% | 5.18% |
| Average Basic Shares Outstanding | -0.08% | -0.08% | -0.08% | -0.16% | -0.28% |
| Average Diluted Shares Outstanding | 0.32% | 0.10% | -0.42% | -0.63% | -0.65% |
| Dividend Per Share | 2.63% | 2.65% | 2.67% | 2.68% | 2.70% |
| Payout Ratio | -0.83% | -0.92% | 11.14% | 46.95% | 4.35% |